There are 33 resources available
36MO - Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
Presenter: Antonio Jose Gonzalez Martin
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
37MO - Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial
Presenter: Lingya Pan
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 36MO and 37MO
Presenter: Rebecca Kristeleit
Session: Mini Oral session
Resources:
Slides
Webcast
39MO - Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer
Presenter: Romain Boidot
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
1MO - Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC)
Presenter: Marcia Hall
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO
Presenter: Iain McNeish
Session: Mini Oral session
Resources:
Slides
Webcast
40MO - Targetable Gene Mutations in Mucinous Ovarian Cancer
Presenter: Sarah Levi
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
State-of-the-art management in carcinosarcoma: From the biology to treatment
Presenter: Ignacio Romero
Session: Rare cancers
Resources:
Slides
Webcast
Is immune therapy definitely required for all clear cell carcinoma?
Presenter: Alexandra Leary
Session: Rare cancers
Resources:
Slides
Webcast
Which drugs could be relevant for LGSC: The present and future
Presenter: Charlie Gourley
Session: Rare cancers
Resources:
Slides
Webcast